Step aside Ozempic and Wegovy — ‘landmark’ trial results for weight-loss drug Mounjaro just dropped, and they – Business Insider India

1. Step aside Ozempic and Wegovy — ‘landmark’ trial results for weight-loss drug Mounjaro just dropped, and they Business Insider India
2. Lilly’s SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes | Eli Lilly and Company Investors | Eli Lilly and Company
3. ADA 2023 – Toxicity undermines Boehringer and Zealand’s incretin Evaluate Pharma
4. Lilly’s phase 2 results published in the New England Journal of Medicine show orforglipron, a once-daily oral nonpeptide GLP-1 receptor agonist, achieved up to 14.7% mean weight reduction at 36 weeks in adults with obesity or overweight Yahoo Finance
5. Lilly’s Mounjaro Gives Positive Results in Obese Diabetic People Bloomberg

Read original article here